AIMT News and Press, Aimmune Therapeutics Inc. From 11/08/19

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today revealed that the logistical needs for implementing oral immunotherapy (OIT) for food allergies, such as peanut allergy, into clinical practice is...

—Despite Differing Study Designs, Patient Criteria and Geographies of the Two Landmark Clinical Trials, Results Were Consistent for AR101-Treated Patients Compared to Placebo— Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for ...

Biotech Pulse Biotech finally has a pulse. The improving appetite for risk has resuscitated the moribund biotechs and pharma (biopharma) groups. The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have begun their advance from their year-to-date lows recorded earlier in Octo...

Aimmune Therapeutics, Inc. (AIMT) Q3 2019 Results Earnings Conference Call November 06, 2019, 04:30 PM ET Company Participants DeDe Sheel - Vice President of Investor Relations Eric Bjerkholt - Chief Financial Officer Jayson Dallas - President and Chief Executive Officer Andrew...

Aimmune Therapeutics (NASDAQ: AIMT ): Q3 GAAP EPS of -$1.03 in-line. More news on: Aimmune Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

--Webcast and conference call today at 4:30 p.m. ET-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced financial results for the quarter and nine months ended September 30, 2019...

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in a fireside chat at the Credit Suisse 28 th Annual Healthcare ...

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced it will present new data on the safety and efficacy of the company’s lead investigational candidate, AR101 (trade name Palforzia&...

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will host a conference call on Wednesday, November 6, 2019, at 4:30 p.m. ET to discuss its financial results for the quarter en...

According to industry and sector data analysed by GlobalData, Merck's ( MRK ) Keytruda will reportedly become the world's top-selling drug by 2025, with estimated sales of over $22 billion. Wall Street consensus estimate pegs nearly $20 billion annual sales for Keytruda by 2023. Bristol-Myer...